Use of anti-CD2 antibody drug conjugate (ADC) in allogeneic cell therapy

摘要

The present invention provides a method of reducing Cd2 + cells to facilitate the acceptance of immune cells expressing the car in human patients undergoing chimeric antigen receptor (car) immunotherapy.An anti-CD2 antibody drug conjugate (ADC) is administered as a conditioned regimen for human patients to receive the immune cells expressing the car in a patient receiving an immune cell expressing a self or allogeneic car.The compositions and methods of the present invention may be used in conjunction with car therapy to treat various pathologies, including autoimmune disease and cancer.